← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Third-generation cephalosporins
ceftibuten
J01DD14
Forms & Strengths
- Capsule: 400 mg
- Oral suspension: 37.5 mg/5 mL
Adult Dosing
- Acute bacterial exacerbation of chronic bronchitis: 400 mg orally once daily for 10 days
- Acute bacterial otitis media: 400 mg orally once daily for 10 days
- Pharyngitis and tonsillitis: 400 mg orally once daily for 10 days
Pediatric Dosing
- Children 6 months to 11 years: 9 mg/kg (maximum 400 mg) orally once daily for 10 days
- Acute bacterial otitis media: 9 mg/kg once daily
- Pharyngitis and tonsillitis: 9 mg/kg once daily
Indications
- Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae
- Acute bacterial otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pyogenes
- Pharyngitis and tonsillitis caused by Streptococcus pyogenes
Mechanism of Action
- Third-generation cephalosporin antibiotic
- Inhibits bacterial cell wall synthesis by binding to one or more penicillin-binding proteins (PBPs)
- Resistant to hydrolysis by many beta-lactamases
Contraindications
- Hypersensitivity to ceftibuten, cephalosporins, or any component of the formulation
- History of immediate hypersensitivity reaction to penicillins or other beta-lactams
Adverse Reactions
- Nausea
- Diarrhea
- Headache
- Dizziness
- Dyspepsia
- Abdominal pain
- Vomiting
Drug Interactions
- Antacids may decrease the rate and extent of absorption
- Probenecid may increase serum concentrations of cephalosporins by decreasing renal excretion
- May enhance the anticoagulant effect of vitamin K antagonists (e.g., warfarin)
Curated Content: Needs Vetting Before Put to Clinical Use